Skip to main content
. 2021 Mar 23;71(3):509–520. doi: 10.1136/gutjnl-2020-323363

Figure 5.

Figure 5

Lack of GPR35 results in reduced MMP levels. (A) MMP levels in Gpr35 +/+ and Gpr35 –/– adenomas. Tissue extract MMPs were activated with APMA. Area under the curve was analysed using image J. N=6 tumours per genotype. (B) MMP levels in M1 and M2 BMDM supernatants from Gpr35 +/+ and Gpr35 –/– mice. Supernatants were APMA-activated. area under the curve was analysed using image J N=9 mice per genotype. (C) MMP levels in M2 macrophages pretreated with ouabain (100 µM) or pNaKtide (1 µM). Area under the curve was analysed using image J N=6 mice per genotype. (D) Total (inactive zymogen and active enzyme) MMP2 and MMP9 levels in tumour tissue from Gpr35fl/fl and Gpr35 ΔMΦ mice. (E) MMP2 and MMP9 levels from M2 murine BMDM supernatants. (F) Total (inactive zymogen and active enzyme) MMP2 levels from supernatants of human iPS cell-derived macrophages. Macrophages were polarised to M0, M1 and M2 macrophages. All data represented as mean±SEM. Statistical significance was calculated using Mann-Whitney U after Kruskal-Wallis testing. * p<0.05, ** p<0.01/ APMA, aminophenylmercuric acetate; MMP, matrix-metallo-proteinase; n.s., not significant; WT, wild type.